The short version of Thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Elsewhere, the successful October Revolution in Russia had facilitated the German Revolution of 1918–1919 and revolutions and interventions in Hungary (1918–1920) which produced the First Hungarian Republic and the Hungarian Soviet Republic. In Berlin, the German government aided by Freikorps units fought and defeated the Spartacist uprising which began as a general strike. In Munich, the local Freikorps fought and defeated the Bavarian Soviet Republic. In Hungary, the disorganised workers who had proclaimed the Hungarian Soviet Republic were fought and defeated by the royal armies of the Kingdom of Romania and the Kingdom of Yugoslavia as well as the army of the First Republic of Czechoslovakia. These communist forces were soon crushed by anti-communist forces and attempts to create an international communist revolution failed. However, a successful revolution occurred in Asia, when the Mongolian Revolution of 1921 established the Mongolian People's Republic (1924–1992). The percentage of Bolshevik delegates in the All-Russian Congress of Soviets increased from 13%, at the first congress in July 1917, to 66%, at the fifth congress in 1918. As promised to the Russian peoples in October 1917, the Bolsheviks quit Russia's participation in the Great War on 3 March 1918. That same year, the Bolsheviks consolidated government power by expelling the Mensheviks, the Socialist Revolutionaries and the Left Socialist-Revolutionaries from the soviets.
== Research == Sarkar discovered copper-histidine in human blood. He invented the treatment of Menkes disease by copper-histidine. He discovered the amino terminal Cu (II)- and Ni (II)- binding (ATCUN) motif of proteins. This motif has been used to cleave DNA, applied as a paramagnetic probe, and used to kill Ehrlich cells. His laboratory identified and characterized the six copper-binding sites of copper-ATPase that is defective in Wilson's disease. He pioneered the development of metalloproteomics, a subdiscipline of proteomics that attempts to identify and characterize all metal-associated proteins in a well-defined system. He also contributed to global health research in Bangladesh, India, Nepal, and Myanmar, where tens of thousands of people are exposed to naturally occurring arsenic and other toxic metals in drinking water from underground wells. Sarkar is considered a pioneer in establishing inorganic biochemistry through his research in the early 1960s. He organized the first international meeting of Biological Inorganic Chemistry in the boardroom of the Hospital for Sick Children in 1972. This initiative was followed by the 56th Nobel Symposium in Inorganic Biochemistry held in Sweden under the auspices of the Nobel Foundation in 1982, where Sarkar was an invited speaker. He has published extensively in scientific journals, organized many series of international symposia on metals and genetics, and edited several books on metals in biology, genetics, and environment.
Some ANAs appear in several types of disease, resulting in lower specificity of the test. For example, IgM-rheumatoid factor (IgM-RF) have been shown to cross-react with ANA giving falsely positive immunofluorescence. Positive ANA as well as anti-DNA antibodies have been reported in patients with autoimmune thyroid disease. ANA can have a positive test result in up to 45% of people with autoimmune thyroid conditions or rheumatoid arthritis and up to 15% of people with HIV or hepatitis C. As per Lupus Foundation of America, "about 5% of the general population will have a positive ANA. However, at least 95% of the people who have a positive ANA do not have lupus. A positive ANA test can sometimes run in families, even if family members have no evidence of lupus." On the other hand, they say, although 95% of the patients who actually have lupus test positive for ANA, "Only a small percentage have a negative ANA, and many of those have other antibodies (such as anti-phospholipid antibodies, anti-Ro, anti-SSA) or their ANA converted from positive to negative from steroids, cytotoxic medications, or uremia (kidney failure)."
Sources: en.wikipedia.org
cell surface receptor Any of a class of receptor proteins embedded within or attached to the external surface of the cell membrane, with one or more binding sites facing the extracellular environment and one or more effector sites that couple the binding of a particular ligand to an intracellular event or process. Cell surface receptors are a primary means by which environmental signals are received by the cell and transmitted across the membrane into the cell interior. Some may also bind exogenous ligands and transport them into the cell in a process known as receptor-mediated endocytosis.
Amino acid-based formula is a type of infant milk formula made from individual amino acids. It is hypoallergenic and intended for infants suffering from severe allergy to milk and various gastrointestinal conditions, such as food protein-induced enterocolitis syndrome and malabsorption syndromes. It is sometimes referred to as elemental formula but this is considered a misleading name. Issues with the use of amino acid-based formula include its high cost and its unpalatable taste. Intake of amino-acid formula for healthy infants shows no advantage in growth.
Such enthusiasm to use the Bryant Park name would have been nonexistent in the 1980s, when the area was described as "the Wild West". New real-estate developments were also built in the park's vicinity starting in the 21st century, which together added over 13,000 new workers to the area immediately surrounding Bryant Park. These included the Bank of America Tower; an expansion to 1095 Avenue of the Americas immediately to the south; Eleven Times Square a block west of Bryant Park; and 505 Fifth Avenue at Fifth Avenue and 42nd Street. Several hotels were also built, including a conversion of 485 Fifth Avenue at 41st Street, a Residence Inn by Marriott at Sixth Avenue and 39th Street. By the early 2010s, investors were purchasing buildings around Bryant Park south of 42nd Street as part of a small real estate boom. Rents per square foot in buildings south of 42nd Street had historically been lower than rents in buildings north of 42nd Street. Conversely, 1095 Avenue of the Americas and 452 Fifth Avenue were able to attract comparatively high rental rates despite both being south of 42nd Street. Later in the decade, the area around Bryant Park started growing into a residential neighborhood, with the construction of new developments in the area. Within a two-block radius of the park, or roughly 500 feet (150 m), units routinely sold for millions of dollars. By 2024, the Bryant Park Grill's lease was about to expire.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.